Scienmag

DECEMBER 18, 2020

Columbus-based company has a novel approach to treat injury and disease by repairing DNA damage Columbus, OH – Dec.

Licensing 40

Licensing Licensing DNA Research 40

BioPharma Reporter

JUNE 24, 2021

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).

DNA 64

DNA Licensing Licensing Antibody 64

Pharmaceutical Technology

MARCH 24, 2023

Under the terms of the deal, Moderna has purchased an option to license ctLNP and closed-ended DNA (ceDNA) technology from Generation Bio. Moderna will have an additional option to license a third programme targeting either immune cells or the liver.

Genetics 130

Genetics Medicine Development In-Vivo 130

The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec.

Licensing 52

Licensing Licensing Bioavailability DNA 52

BioPharma Reporter

JULY 20, 2023

Twist Bioscience, a biotech company manufacturing synthetic DNA, and Cancer Research Horizons, the innovation engine at the core of Cancer Research UK, have announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.

Research 40

Research DNA Engineer Licensing 40

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Drug Discovery World

JANUARY 19, 2023

The products, tools, talent and licensed technology will enable us to grow our NGS platform and unlock new market opportunities for IDT.” The post Key acquisition for next generation sequencing research assays appeared first on Drug Discovery World (DDW).

Research 52

Research DNA Licensing Licensing 52

Roots Analysis

FEBRUARY 27, 2024

Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Drug Discovery World

MAY 5, 2023

The deal also provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs). “We We are excited to bring this powerful platform into Eterna.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

AUGUST 21, 2023

Transcription factors are proteins that control every gene in a person’s genome by binding to DNA and flipping the on/off switches that govern gene expression. Talus Bio was also awarded a $2.0M When they go awry, they often drive cancer and other disease processes like diabetes, inflammatory diseases, and neurological conditions.

Drugs 98

Drugs Gene Expression Protein Gene 98

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially to treat tumours. It’s also providing research funding.

DNA 52

DNA Licensing Licensing Gene Therapy 52

BioTech 365

OCTOBER 15, 2020

Aegis Life is launched to pursue US-based development and commercialization of SARS-CoV-2 vaccine using the Entos Fusogenix technology and to support manufacturing and distribution of millions of DNA vaccine doses globally Aegis Life signs a license agreement with Nature Technology … Continue reading →

Vaccination 40

Vaccination Vaccine DNA Licensing 40

BioTech 365

OCTOBER 15, 2020

Aegis Life is launched to pursue US-based development and commercialization of SARS-CoV-2 vaccine using the Entos Fusogenix technology and to support manufacturing and distribution of millions of DNA vaccine doses globally Aegis Life signs a license agreement with Nature Technology … Continue reading →

Vaccination 52

Vaccination Vaccine DNA Licensing 52

The Pharma Data

MARCH 30, 2021

Targeted radioligand therapy is a type of precision medicine combining two key elements: a targeting compound, or ligand, and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. We believe this technology has the potential to transform many patients’ lives.”.

Protein 52

Protein Licensing Licensing Containment 52

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio.

Gene Sequencing 71

Gene Sequencing DNA Vaccination Vaccine 71

Drug Discovery World

OCTOBER 6, 2023

Researchers uncover molecular pathways underlying depression Scientists have discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets.

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

AUGUST 28, 2020

In the phase 2a trial, GSK3228836 was able to reduce two biomarkers of chronic HBV infection – hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA – compared to placebo after four weeks treatment. Meanwhile, five of 12 previously-untreated patients had 2-log (90%) or a greater reduction in HBV DNA.

Drugs 52

Drugs DNA Licensing Licensing 52

pharmaphorum

JUNE 27, 2022

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks’ treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes that it could offer permanent cure, allowing safe termination of antiviral therapy.

DNA 104

DNA Drugs Sales Licensing 104

pharmaphorum

NOVEMBER 5, 2021

There have also been come concerns about the risk of birth defects with molnupiravir due to its mechanism of action that can lead to DNA changes, and Pfizer has been quick to point out that it has found no evidence of “mutagenic DNA interactions” with its protease inhibitor.

Contract Manufacturing 100

Contract Manufacturing DNA HR Manufacturing 100

XTalks

DECEMBER 13, 2023

Xoma’s unique approach involves acquiring future economic interests tied to pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotech companies. It is now progressing towards the submission of a Biologics License Application (BLA) by the end of 2023. million, compared to $1.1

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

MAY 22, 2023

Related: 5 Food Companies Working With Precision Fermentation Technology How Pairwise Leverages CRISPR Technology CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technique that can be used to alter the DNA of cells to enhance certain characteristics or reduce less desirable ones.

Branding 98

Branding Gene Editing DNA Production 98

pharmaphorum

FEBRUARY 19, 2021

Once someone is infected with HIV it stays with them for life thanks to the retrovirus’s ability to inject its DNA code into the host. Excision wants to take its lead therapy candidate, EBT-101, into a phase 1/2 clinical trial in patients with chronic HIV infection with the proceeds from this latest financing round.

Gene Editing 102

Gene Editing In-Vivo DNA In-Vitro 102

Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 52

Drugs Gene Expression Engineer Gene 52

pharmaphorum

NOVEMBER 19, 2021

There have also been come concerns about the risk of birth defects with molnupiravir due to its mechanism of action that can lead to DNA changes, and Pfizer has been quick to point out that it has found no evidence of “mutagenic DNA interactions” with its protease inhibitor.

Drugs 98

Drugs DNA Vaccination Vaccine 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

APRIL 22, 2022

Astellas also revealed today that it is terminating the development of ASP2390, a DNA vaccine for house dust mite-induced allergic rhinitis, and GITR agonist antibody ASP1951 for cancer – both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753.

Gene Therapy 97

Gene Therapy Gene DNA Licensing 97

Drug Discovery World

AUGUST 23, 2022

ASTX727 is an orally administered, fixed-dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine, an inhibitor of cytidine deaminase (CDA). .

Clinical Trials 52

Clinical Trials Clinical Trials DNA Licensing 52

pharmaphorum

OCTOBER 3, 2022

Translarna was the first licensed treatment for DMD which addresses the loss of dystrophin. A gene therapy, it permits the body to read over the DNA mutation and still continue to produce dystrophin. Eventually, they will need assistance with breathing.

Gene Therapy 75

Gene Therapy Gene FDA Approval DNA 75

pharmaphorum

MAY 7, 2021

Founded by Nobel prize winner Emmanuelle Charpentier, CRISPR Therapeutics has been at the forefront of the gene editing technology and has refined it to the point where it can be used to accurately edit DNA to correct genetic conditions or modify cells to fight disease.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

Delveinsight

DECEMBER 1, 2020

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research. US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting. CABOMETYX is already approved in the U.S.

Antibody 52

Antibody DNA Clinical Trials Clinical Trials 52

Drug Discovery World

JUNE 5, 2023

Auger emitters such as I-123 combined with a PARP inhibitor enable delivery of radionuclides to the DNA to selectively kill cancer cells whilst sparing healthy tissue, thereby offering a potentially powerful treatment option in several cancer indications.

FDA Approval 52

FDA Approval DNA Production Licensing 52

The Pharma Data

JUNE 7, 2023

In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA. “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

XTalks

JUNE 20, 2022

Alnylam’s Onpattro was its first licensed and approved RNAi therapy for ATTR polyneuropathy. XTALKS WEBINAR: Liquid Biopsy Workflow Optimization for Improved Assay Sensitivity and Multianalyte Applications of Cell-Free RNA, DNA and CTCs. These abnormalities can lead to progressive heart failure and death.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

NOVEMBER 9, 2022

In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants with chronic HBV infection.

Drugs 87

Drugs Sales Trials DNA 87

Drug Discovery World

APRIL 5, 2023

Mechanism of action HSF1 is a transcription factor, meaning that it controls the production of other important proteins in the cell, through its regulation of the process of reading the genetic code stored in DNA. NXP800 has been licensed to oncology-focused biopharmaceutical company Nuvectis Pharma, which is leading the further development.

Drugs 52

Drugs Scientist Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. based Horizon Discovery Group granted a license to China’s Sanyou Biopharmaceuticals Co. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

JANUARY 30, 2022

Top of the list was Oxford Nanopore’s stellar debut on the London Stock Exchange at the end of September, raising £350 million and propelling the vale of the DNA sequencing specialist up towards the £5 billion mark. The post Offshore warning as UK biotech investment rises sharply in 2021 appeared first on.

Life Science 88

Life Science Allergies DNA Licensing 88